Use of Lung Ultrasound in Evaluating Physiological Response to Awake Self Proning

November 11, 2021 updated by: Jie Li, Rush University Medical Center
The primary objective of this study is to explore the physiological mechanism of awake, self proning among patients with acute hypoxemic respiratory failure induced by COVID-19, using LUS in the first three days and explore the predictive value of LUS in patients' outcome.

Study Overview

Status

Completed

Conditions

Detailed Description

Lung ultrasound (LUS) has recently gained popularity among the imaging methods to perform bedside assessment of critically ill patients to guide clinical management. LUS is a non-invasive and easy-to-perform procedure that provides precise data on lung aeration, lung recruitment, lung morphology, and lung perfusion. Studies have shown that LUS is a useful tool in monitoring lung reaeration in intubated patients diagnosed with traditional ARDS undergoing prone positioning; however there are mixed findings in terms of the use of LUS in predicting potential prone positioning response. A recent study found that the non-intubated COVID-19 patients who responded to prone positioning had more pronounced disturbances of aeration in posterior regions, however, they only investigated patients' response to the first prone positioning and the information for the patients' outcome is lacking. In our previous study with intubated COVID-19 patients, we found that patients' response to the subsequent prone positioning had higher predictive value than the response to the first prone positioning. Therefore, the primary objective of this study is to explore the physiological mechanism of awake, self proning among patients with acute hypoxemic respiratory failure induced by COVID-19, using LUS in the first three days and explore the predictive value of LUS in patients' outcome.

Study Type

Observational

Enrollment (Actual)

74

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44280
        • Hospital Civil Fray Antonio Alcalde
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Rush University Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients with acute hypoxemic respiratory failure due to COVID-19 who are admitted at Rush University Medical Center

Description

Inclusion Criteria:

  1. Adult subjects 18 years and older,
  2. Confirmed COVID-19 diagnosis
  3. Acute hypoxemic respiratory failure (SpO2/FiO2 or PaO2/FiO2 <300)
  4. Ordered self-prone positioning per medical team

Exclusion Criteria:

  1. Pregnant
  2. Palliative care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SpO2/FiO2 pre prone in day 1
Time Frame: pre prone in day 1
Patients' response of oxygenation using SpO2/FiO2
pre prone in day 1
SpO2/FiO2 post prone in day 1
Time Frame: post prone in day 1
Patients' response of oxygenation using SpO2/FiO2
post prone in day 1
SpO2/FiO2 pre prone in day 2
Time Frame: Pre prone in day 2
Patients' response of oxygenation using SpO2/FiO2
Pre prone in day 2
SpO2/FiO2 post prone in day 2
Time Frame: Post prone in day 2
Patients' response of oxygenation using SpO2/FiO2
Post prone in day 2
SpO2/FiO2 pre prone in day 3
Time Frame: Pre prone in day 3
Patients' response of oxygenation using SpO2/FiO2
Pre prone in day 3
SpO2/FiO2 post prone in day 3
Time Frame: Post prone in day 3
Patients' response of oxygenation using SpO2/FiO2
Post prone in day 3
Lung Ultrasound Score pre prone in day 1
Time Frame: Pre prone in day 1
Patients' response of oxygenation using Lung ultrasound score
Pre prone in day 1
Lung Ultrasound Score post prone in day 1
Time Frame: Post prone in day 1
Patients' response of oxygenation using Lung ultrasound score
Post prone in day 1
Lung Ultrasound Score pre prone in day 2
Time Frame: Pre prone in day 2
Patients' response of oxygenation using Lung ultrasound score
Pre prone in day 2
Lung Ultrasound Score post prone in day 2
Time Frame: Post prone in day 2
Patients' response of oxygenation using Lung ultrasound score
Post prone in day 2
Lung Ultrasound Score pre prone in day 3
Time Frame: Pre prone in day 3
Patients' response of oxygenation using Lung ultrasound score
Pre prone in day 3
Lung Ultrasound Score post prone in day 3
Time Frame: Post prone in day 3
Patients' response of oxygenation using Lung ultrasound score
Post prone in day 3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jie Li, Rush University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 21, 2021

Primary Completion (Actual)

October 7, 2021

Study Completion (Actual)

October 23, 2021

Study Registration Dates

First Submitted

April 13, 2021

First Submitted That Met QC Criteria

April 21, 2021

First Posted (Actual)

April 22, 2021

Study Record Updates

Last Update Posted (Actual)

November 15, 2021

Last Update Submitted That Met QC Criteria

November 11, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • 21040601

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Subscribe